Quinishal

Posted September 23, 2018

Quinishal

Quinishal is indicated mainly in the uncomplicated strains of P. falciparum malaria. Consideration must be given to the WHO guidelines and to local health authorities

Product	Molecule
Quinishal Suspension	Quinine
Quinishal Injectables	Quinishal

Molecule: Quinine

Formulation: Quinine Sulphate Suspension 100 mg/5 ml

Packaging Unit: 60ml Suspension

Dosage: For the treatment of P. falciparum Malaria a course usually lasts 7 days.

View PDF

Molecule: Quinishal

Formulation: Quinishal 250mg/2ml, 500mg/2ml, 600mg/2ml Injection

Packaging Unit: 100 Ampoules

Dosage: For the treatment of P. falciparum Malaria a course usually lasts 7 days.

View PDF

Indications

Quinishal is indicated mainly in the uncomplicated strains of P. falciparum malaria. Consideration must be given to the WHO guidelines and to local health authorities recommendations based on the prevalence of resistance to antimalarial agents.

Pharmacological Class

Pharmacological Properties

Mechanism Of Action

Quinine is a rapidly acting blood schizontocide. It inhibits protein synthesis by preventing strand separation and therefore DNA replication and transcription to RNA.

Side Effects

Contraindications

Quinine and its salts are contra-indicated in patients with a history of hypersensitivity to quinine and in patients with tinnitus or optic neuritis and especially when this takes the form of cutaneous, angioedematous, visual, or auditory symptoms. Quinine should be discontinued immediately if evidence of haemolysis appears. As quinine has been implicated in precipitating blackwater fever, it is generally contraindicated in patients who have already suffered an attack. Quinine should be avoided in patients with myasthenia gravis, as it may aggravate their condition.

Observations